Improved understanding of molecular drivers of carcinogenesis has led to significant
progress in the management of lung cancer. Patients with non-small-cell lung cancer …

The implementation of cancer genomic testing into the clinical setting has brought major
opportunities. However, as our understanding of cancer initiation, maintenance and …

Introduction Mutant BRAF is a driver oncogene found in 2% of lung adenocarcinomas and
represents a target for therapy. We examined the clinical characteristics and course of …

The therapeutic landscape of non–small-cell lung cancer (NSCLC) has dramatically
changed in the last few years with the introduction of molecularly targeted agents, leading to …

KRAS mutations are the most common mutations in non-small cell lung cancer (NSCLC)
with adenocarcinoma histology. KRAS mutations result in the activation of the RAF–MEK …

Tumor tissue biomarkers are the basis for targeted therapy in non-small cell lung cancer
(NSCLC). These biomarkers either reflect the target of the specific drug or some factor that …

Lung adenocarcinoma is the most common subtype of lung cancer today. With the discovery
of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) …

Lung cancer remains the leading cause of cancer death in the United States. It is estimated
that 228 190 patients were diagnosed with the disease and 159 480 died of lung cancer in …

Diffuse intrinsic pontine glioma (DIPG) is one of the deadliest pediatric central nervous
system cancers in spite of treatment with radiation therapy, the current standard of care. The …

Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide.
The majority (85%) of cases are histologically proven non-small cell lung carcinomas …